Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Treatment of Leptomeningeal Carcinomatosis in a Patient with Metastatic Pancreatic Cancer: A Case Report and Review of the Literature.

Johnson WR, Theeler BJ, Van Echo D, Young P, Kwok M.

Case Rep Oncol. 2018 May 17;11(2):281-288. doi: 10.1159/000489085. eCollection 2018 May-Aug.

2.

Gallbladder Carcinoma, the Difficulty of Early Detection: A Case Report.

Graff AE, Lewis SL, Bear JR, Van Echo DC, Dainer HM.

Cureus. 2016 Feb 12;8(2):e493. doi: 10.7759/cureus.493.

3.

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.

Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE.

Ann Oncol. 2014 Sep;25(9):1735-42. doi: 10.1093/annonc/mdu211. Epub 2014 Jun 6.

4.

Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.

Chiappori A, Williams C, Northfelt DW, Adams JW, Malik S, Edelman MJ, Rosen P, Van Echo DA, Berger MS, Haura EB.

J Thorac Oncol. 2014 Jan;9(1):121-5. doi: 10.1097/JTO.0000000000000027.

5.

AE37: a novel T-cell-eliciting vaccine for breast cancer.

Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, Holmes JP, Shumway NM, Van Echo DC, Carmichael MG, Ponniah S, Baxevanis CN, Mittendorf EA, Papamichail M, Peoples GE.

Expert Opin Biol Ther. 2011 Nov;11(11):1543-50. doi: 10.1517/14712598.2011.616889. Epub 2011 Sep 6. Review.

PMID:
21895539
6.

Computer assisted quantitative immunofluorescence of tumor tissue marker expression and clinical outcome to chemotherapy in advanced breast cancer patients.

Tkaczuk KH, Tait NS, Ioffe O, Tan M, Goloubeva OG, Lesko SA, Deamond SF, Zhou D, Lum ZP, Sutula MJ, Van Echo D, Ts'o PO.

Discov Med. 2011 Jul;12(62):33-40.

7.

Gram-negative multidrug-resistant organism colonization in a US military healthcare facility in Iraq.

Ake J, Scott P, Wortmann G, Huang XZ, Barber M, Wang Z, Nikolich M, Van Echo D, Weintrob A, Lesho E.

Infect Control Hosp Epidemiol. 2011 Jun;32(6):545-52. doi: 10.1086/660015.

PMID:
21558766
8.

The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.

Saito K, Khan K, Yu SZ, Ronson S, Rhee J, Li G, Van Echo D, Suntharalingam M, O'Malley BW Jr, Li D.

Laryngoscope. 2009 Jan;119(1):82-8. doi: 10.1002/lary.20003.

PMID:
19117293
9.

The significance of circulating epithelial cells in Breast Cancer patients by a novel negative selection method.

Tkaczuk KH, Goloubeva O, Tait NS, Feldman F, Tan M, Lum ZP, Lesko SA, Van Echo DA, Ts'o PO.

Breast Cancer Res Treat. 2008 Sep;111(2):355-64. Epub 2007 Dec 7.

PMID:
18064568
10.

The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.

Roberts ZJ, Goutagny N, Perera PY, Kato H, Kumar H, Kawai T, Akira S, Savan R, van Echo D, Fitzgerald KA, Young HA, Ching LM, Vogel SN.

J Exp Med. 2007 Jul 9;204(7):1559-69. Epub 2007 Jun 11.

11.

Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.

Cunningham SC, Cusnir M, Burdick RK, Van Echo DA, Moesinger R.

Clin Adv Hematol Oncol. 2003 Dec;1(12):741-2; discussion 743. No abstract available.

PMID:
16258479
13.

An exploration of relative health stock in advanced cancer patients.

Gaskin DJ, Weinfurt KP, Castel LD, DePuy V, Li Y, Balshem A, Benson A, Burnett CB, Corbett S, Marshall J, Slater E, Sulmasy DP, Van Echo D, Meropol NJ, Schulman KA.

Med Decis Making. 2004 Nov-Dec;24(6):614-24.

PMID:
15534342
14.

Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication.

Meropol NJ, Weinfurt KP, Burnett CB, Balshem A, Benson AB 3rd, Castel L, Corbett S, Diefenbach M, Gaskin D, Li Y, Manne S, Marshall J, Rowland JH, Slater E, Sulmasy DP, Van Echo D, Washington S, Schulman KA.

J Clin Oncol. 2003 Jul 1;21(13):2589-96.

PMID:
12829680
15.

Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer.

Haddad RI, Van Echo DA.

Cancer Chemother Pharmacol. 2003 Oct;52(4):303-6. Epub 2003 Jun 25.

PMID:
12827298
16.

Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer.

Bray D, Yu SZ, Koprowski H 2nd, Rhee J, Kumar S, Pericle F, Suntharalingam M, Van Echo DA, Li D, O'Malley BW Jr.

Arch Otolaryngol Head Neck Surg. 2003 Jun;129(6):618-22.

PMID:
12810463
17.

Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug.

Edelman MJ, Bauer K, Khanwani S, Tait N, Trepel J, Karp J, Nemieboka N, Chung EJ, Van Echo D.

Cancer Chemother Pharmacol. 2003 May;51(5):439-44. Epub 2003 Mar 12.

PMID:
12736763
18.

Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors.

Sarfaraz M, Kennedy AS, Cao ZJ, Sackett GD, Yu CX, Lodge MA, Murthy R, Line BR, Van Echo DA.

Med Phys. 2003 Feb;30(2):199-203.

PMID:
12607837
19.

Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.

Li D, Ronson B, Guo M, Liu S, Bishop JS, Van Echo DA, O'Malley BW Jr.

Cancer Res. 2002 Jul 15;62(14):4023-8.

20.

Pleurx tunneled catheter in the management of malignant ascites.

Richard HM 3rd, Coldwell DM, Boyd-Kranis RL, Murthy R, Van Echo DA.

J Vasc Interv Radiol. 2001 Mar;12(3):373-5.

PMID:
11287517
21.

Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck.

Suntharalingam M, Haas ML, Van Echo DA, Haddad R, Jacobs MC, Levy S, Gray WC, Ord RA, Conley BA.

Cancer. 2001 Feb 1;91(3):548-54.

PMID:
11169937
22.

Phase I study of docetaxel and topotecan in patients with solid tumors.

Tkaczuk KH, Zamboni WC, Tait NS, Meisenberg BR, Doyle LA, Edelman MJ, Hausner PF, Egorin MJ, Van Echo DA.

Cancer Chemother Pharmacol. 2000;46(6):442-8.

PMID:
11138457
23.

Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors.

Zamboni WC, Egorin MJ, Van Echo DA, Day RS, Meisenberg BR, Brooks SE, Doyle LA, Nemieboka NN, Dobson JM, Tait NS, Tkaczuk KH.

J Clin Oncol. 2000 Sep 15;18(18):3288-94.

PMID:
10986062
24.

The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.

Suntharalingam M, Haas ML, Conley BA, Egorin MJ, Levy S, Sivasailam S, Herman JM, Jacobs MC, Gray WC, Ord RA, Aisner JA, Van Echo DA.

Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):49-56.

PMID:
10758304
25.

Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma.

Park SH, Gray WC, Hernandez I, Jacobs M, Ord RA, Sutharalingam M, Smith RG, Van Echo DA, Wu S, Conley BA.

Clin Cancer Res. 2000 Mar;6(3):847-54.

26.

Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.

Conley BA, Egorin MJ, Tait N, Rosen DM, Sausville EA, Dover G, Fram RJ, Van Echo DA.

Clin Cancer Res. 1998 Mar;4(3):629-34.

27.

Cytoablative therapy with combined resection and cryosurgery for limited bilobar hepatic colorectal metastases.

Johnson LB, Krebs TL, Van Echo D, Plotkin JS, Njoku M, Wong JJ, Daly BD, Kuo PC.

Am J Surg. 1997 Dec;174(6):610-3.

PMID:
9409583
28.

Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics.

Conley BA, Egorin MJ, Sridhara R, Finley R, Hemady R, Wu S, Tait NS, Van Echo DA.

Cancer Chemother Pharmacol. 1997;39(4):291-9.

PMID:
9025769
29.

A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study.

Mitchell EP, Perry MC, Luikart SD, Cirrincione CT, Van Echo DA, Herndon JE 2nd, Maurer LH, Clamon G, Green MR.

Lung Cancer. 1996 Sep;15(2):215-23.

PMID:
8882988
30.

Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.

Ratain MJ, Rosner G, Allen SL, Costanza M, Van Echo DA, Henderson IC, Schilsky RL.

J Clin Oncol. 1995 Mar;13(3):741-7.

PMID:
7884434
31.

Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics.

Conley BA, O'Hara S, Wu S, Melink TJ, Parnes H, Pardoe E, Egorin MJ, Van Echo DA.

Cancer Chemother Pharmacol. 1995;37(1-2):139-49.

PMID:
7497583
32.

Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.

Lichtman SM, Ratain MJ, Van Echo DA, Rosner G, Egorin MJ, Budman DR, Vogelzang NJ, Norton L, Schilsky RL.

J Natl Cancer Inst. 1993 Aug 18;85(16):1319-26.

PMID:
8340944
33.

Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer. A report from the Cancer and Leukemia Group B.

Luikart SD, Goutsou M, Mitchell ED, Van Echo DA, Modeas CR, Propert KJ, O'Donnell J, Difino S, Perry MC, Green MR.

Am J Clin Oncol. 1993 Apr;16(2):127-31.

PMID:
8383914
34.

Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin.

Conley BA, Egorin MJ, Whitacre MY, Carter DC, Zuhowski EG, Van Echo DA.

Cancer Chemother Pharmacol. 1993;33(2):107-12.

PMID:
8261569
35.

Predicting genitourinary toxicity in patients receiving cisplatin-based combination chemotherapy: a Cancer and Leukemia Group B study.

Hargis JB, Anderson JR, Propert KJ, Green MR, Van Echo DA, Weiss RB.

Cancer Chemother Pharmacol. 1992;30(4):291-6.

PMID:
1643697
36.

Approaches to optimal dosing of hexamethylene bisacetamide.

Conley BA, Egorin MJ, Sinibaldi V, Sewack G, Kloc C, Roberts L, Zuhowski EG, Forrest A, Van Echo DA.

Cancer Chemother Pharmacol. 1992;31(1):37-45.

PMID:
1333894
37.

Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer.

Aisner J, Whitacre MY, Budman DR, Propert K, Strauss G, Van Echo DA, Perry M.

Cancer Chemother Pharmacol. 1992;29(6):435-8.

PMID:
1314712
38.

Response to high dose cyclophosphamide with GM-CSF in Merkel cell tumor.

Stock W, Lichtman S, Ratain MJ, O'Brein S, Vogelzang NJ, Van Echo DA.

Ann Oncol. 1991 Jul;2(7):522-3. No abstract available.

PMID:
1911464
39.

Tolerance of full dose menogaril (NSC 269148) in patients with abnormal hepatic and renal function.

Conley BA, Egorin MJ, Sinibaldi V, Van Echo DA.

Invest New Drugs. 1990 Nov;8(4):365-7. No abstract available.

PMID:
2150671
40.

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, Sznol M, Dutcher JP, Aronson FR, Doroshow JH, et al.

J Clin Oncol. 1990 Oct;8(10):1650-6.

PMID:
2213101
41.

Hypersensitivity reactions from taxol.

Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B.

J Clin Oncol. 1990 Jul;8(7):1263-8.

PMID:
1972736
42.

Esorubicin (4'-deoxydoxorubicin, NSC 267469) in advanced breast cancer. A phase II study of the CALGB.

Muss HB, Van Echo D, Korzun AH, Henderson IC, Campbell T, Vogelzang NJ, Rice MA, Wood W.

Am J Clin Oncol. 1990 Jun;13(3):233-7.

PMID:
2346128
43.

A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide.

Belani CP, Egorin MJ, Abrams JS, Hiponia D, Eisenberger M, Aisner J, Van Echo DA.

J Clin Oncol. 1989 Dec;7(12):1896-902.

PMID:
2555452
44.

Platinum compounds.

Belani CP, Van Echo DA, Aisner J.

Curr Opin Oncol. 1989 Dec;1(2):186-91. Review. No abstract available.

PMID:
2489958
45.

A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer.

Eisenberger M, Krasnow S, Ellenberg S, Silva H, Abrams J, Sinibaldi V, Van Echo D, Aisner J.

J Clin Oncol. 1989 Sep;7(9):1341-5.

PMID:
2671289
46.

Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).

Conley BA, Forrest A, Egorin MJ, Zuhowski EG, Sinibaldi V, Van Echo DA.

Cancer Res. 1989 Jun 15;49(12):3436-40.

47.

A limited sampling strategy for cyclophosphamide pharmacokinetics.

Egorin MJ, Forrest A, Belani CP, Ratain MJ, Abrams JS, Van Echo DA.

Cancer Res. 1989 Jun 1;49(11):3129-33.

48.

Carboplatin: the experience in head and neck cancer.

Eisenberger M, Van Echo D, Aisner J.

Semin Oncol. 1989 Apr;16(2 Suppl 5):34-41. Review. No abstract available.

PMID:
2655096
49.

The pharmacology of carboplatin.

Van Echo DA, Egorin MJ, Aisner J.

Semin Oncol. 1989 Apr;16(2 Suppl 5):1-6. Review. No abstract available.

PMID:
2655093
50.

Phase II trial of N-methylformamide in advanced renal cancer.

Abrams JS, Tait N, Silva H, Eisenberger M, Van Echo DA, Olver IN, Aisner J.

Am J Clin Oncol. 1989 Feb;12(1):41-2.

PMID:
2912020

Supplemental Content

Loading ...
Support Center